KR20220070477A - 고페닐알라닌혈증 치료 방법 - Google Patents

고페닐알라닌혈증 치료 방법 Download PDF

Info

Publication number
KR20220070477A
KR20220070477A KR1020227013671A KR20227013671A KR20220070477A KR 20220070477 A KR20220070477 A KR 20220070477A KR 1020227013671 A KR1020227013671 A KR 1020227013671A KR 20227013671 A KR20227013671 A KR 20227013671A KR 20220070477 A KR20220070477 A KR 20220070477A
Authority
KR
South Korea
Prior art keywords
day
sepiapterin
subject
per liter
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227013671A
Other languages
English (en)
Korean (ko)
Inventor
니엘 스미스
Original Assignee
피티씨 테라퓨틱스 엠피, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72827023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20220070477(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 피티씨 테라퓨틱스 엠피, 인크. filed Critical 피티씨 테라퓨틱스 엠피, 인크.
Publication of KR20220070477A publication Critical patent/KR20220070477A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020227013671A 2019-09-25 2020-09-25 고페닐알라닌혈증 치료 방법 Pending KR20220070477A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962905720P 2019-09-25 2019-09-25
US62/905,720 2019-09-25
PCT/US2020/052871 WO2021062264A1 (en) 2019-09-25 2020-09-25 Methods for treating hyperphenylalaninemia

Publications (1)

Publication Number Publication Date
KR20220070477A true KR20220070477A (ko) 2022-05-31

Family

ID=72827023

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227013671A Pending KR20220070477A (ko) 2019-09-25 2020-09-25 고페닐알라닌혈증 치료 방법

Country Status (23)

Country Link
US (1) US20220362249A1 (cg-RX-API-DMAC7.html)
EP (1) EP4034122B1 (cg-RX-API-DMAC7.html)
JP (2) JP7661315B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220070477A (cg-RX-API-DMAC7.html)
CN (1) CN114650825A (cg-RX-API-DMAC7.html)
AU (1) AU2020353676B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022003719A2 (cg-RX-API-DMAC7.html)
CA (1) CA3150003A1 (cg-RX-API-DMAC7.html)
DK (1) DK4034122T3 (cg-RX-API-DMAC7.html)
ES (1) ES3041002T3 (cg-RX-API-DMAC7.html)
FI (1) FI4034122T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251268T1 (cg-RX-API-DMAC7.html)
HU (1) HUE073483T2 (cg-RX-API-DMAC7.html)
IL (1) IL291565B1 (cg-RX-API-DMAC7.html)
JO (1) JOP20220042A1 (cg-RX-API-DMAC7.html)
LT (1) LT4034122T (cg-RX-API-DMAC7.html)
MX (1) MX2022003585A (cg-RX-API-DMAC7.html)
PL (1) PL4034122T3 (cg-RX-API-DMAC7.html)
PT (1) PT4034122T (cg-RX-API-DMAC7.html)
RS (1) RS67295B1 (cg-RX-API-DMAC7.html)
SI (1) SI4034122T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500493T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021062264A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
ES2586945T3 (es) * 2014-03-31 2016-10-19 Vasopharm Gmbh Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) * 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) * 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩

Also Published As

Publication number Publication date
MX2022003585A (es) 2022-04-19
ES3041002T3 (en) 2025-11-06
JP2022549834A (ja) 2022-11-29
JOP20220042A1 (ar) 2023-01-30
BR112022003719A2 (pt) 2022-05-31
DK4034122T3 (da) 2025-09-15
EP4034122A1 (en) 2022-08-03
FI4034122T3 (fi) 2025-10-08
RS67295B1 (sr) 2025-11-28
HRP20251268T1 (hr) 2025-12-05
PT4034122T (pt) 2025-09-18
WO2021062264A1 (en) 2021-04-01
SMT202500493T1 (it) 2026-01-12
HUE073483T2 (hu) 2026-01-28
AU2020353676B2 (en) 2026-04-30
JP2025111476A (ja) 2025-07-30
IL291565B1 (en) 2026-04-01
SI4034122T1 (sl) 2025-12-31
US20220362249A1 (en) 2022-11-17
CN114650825A (zh) 2022-06-21
EP4034122B1 (en) 2025-08-13
CA3150003A1 (en) 2021-04-01
PL4034122T3 (pl) 2026-01-26
IL291565A (en) 2022-05-01
AU2020353676A1 (en) 2022-04-14
LT4034122T (lt) 2025-11-10
JP7661315B2 (ja) 2025-04-14

Similar Documents

Publication Publication Date Title
AU2020353676B2 (en) Methods for treating hyperphenylalaninemia
US12213982B2 (en) Pharmaceutical compositions comprising sepiapterin and uses thereof
US20250205202A1 (en) Magnesium biotinate compositions and methods of use
EP2763682B1 (en) Choline composition
US20240115572A1 (en) Methods for treating glioblastomas with sepiapterin
EP2065045A1 (en) Antioxidant for preventing and treating diseases caused by oxidative stress
CA3165636A1 (en) Methods for treating parkinson's disease with sepiapterin
HK40081378A (en) Methods for treating hyperphenylalaninemia
HK40081378B (en) Methods for treating hyperphenylalaninemia
EA052959B1 (ru) Способы лечения гиперфенилаланинемии
EA047419B1 (ru) Способы лечения гиперфенилаланинемии
CN109588727B (zh) 一种辅助预防心血管疾病的保健食品
US20190298721A1 (en) Stable pro-vitamin derivative compounds, pharmaceutical and dietary compositions, and methods of their use
RU2775974C2 (ru) Комбинированная терапия для лечения кожных заболеваний
CN115702933A (zh) 一种用于辅助降低血糖的组合物
HK40089668A (en) Composition containing sesamin or like and nr and/or nmn
CN104649953A (zh) 一种沙格列汀倍半水合物化合物
HK1200710B (en) Choline composition

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000